Join
Live feed
·
PRReleasevia Quantisnow
Zealand Pharma A/S logo

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

ByQuantisnow·Wall Street's wire, on your screen.
ZEAL· Zealand Pharma A/S
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZEAL (Zealand Pharma A/S) and more on Quantisnow.